Development of a fast algorithm for automatic delineation of prostate gland on 2D ultrasound images

2012 ◽  
Author(s):  
Hoda Eskandari ◽  
Alireza Talebpour ◽  
Sanaz Hariri Tabrizi ◽  
Mohammad Reza Nowroozi
Keyword(s):  
Fast Algorithm ◽  
Prostate Gland ◽  
Ultrasound Images ◽  
2D Ultrasound

Cell-Based Two-Region Competition Algorithm with a Map Framework for Boundary Delineation of a Series of 2D Ultrasound Images

2007 ◽  
Vol 33 (10) ◽  
pp. 1640-1650 ◽  
Author(s):  
Jie-Zhi Cheng ◽  
Chung-Ming Chen ◽  
Yi-Hong Chou ◽  
Curtis S.K. Chen ◽  
Chui-Mei Tiu ◽  
...  
Keyword(s):  
Ultrasound Images ◽  
2D Ultrasound

Automatic Segmentation of the Cerebral Falx and Adjacent Gyri in 2D Ultrasound Images

2015 ◽  
pp. 287-292 ◽  
Author(s):  
Jennifer Nitsch ◽  
Jan Klein ◽  
Dorothea Miller ◽  
Ulrich Sure ◽  
Horst K. Hahn
Keyword(s):  
Automatic Segmentation ◽  
Ultrasound Images ◽  
2D Ultrasound

scholarly journals MLESAC Based Localization of Needle Insertion Using 2D Ultrasound Images

2018 ◽  
Vol 1004 ◽  
pp. 012037 ◽  
Author(s):  
Fei Xu ◽  
Dedong Gao ◽  
Shan Wang ◽  
A Zhanwen
Keyword(s):  
Needle Insertion ◽  
Ultrasound Images ◽  
2D Ultrasound

Three-dimensional ultrasound-based spectroscopic imaging for the detection of prostate cancer.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 234-234
Author(s):  
Hans T. Chung ◽  
Ervis Sofrani ◽  
Naum Papanicolau ◽  
Linda Sugar ◽  
Gerard Morton ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Prostate Gland ◽  
Spectroscopic Imaging ◽  
Radiotherapy Planning ◽  
Ultrasound Images ◽  
Three Dimension ◽  
Detection Rates ◽  
Whole Mount ◽  
Parametric Maps

234 Background: The objective of this translational research was to investigate the use of real-time novel three-dimension, quantitative ultrasound-based spectroscopic imaging of the prostate as a means of cancer detection. Methods: Fourteen patients with T2-3 prostate cancer underwent a 6–9 MHz trans-rectal ultrasound scan of the prostate prior to radical prostatectomy. Equally spaced axial ultrasound images (0.5 cm separation) corresponding elasticity and spectroscopy data were collected in each patient. Colour-coded spectroscopic parametric maps of 0-Mhz intercept (0-Mhz), mid-band fit (MBF) and slope of line of best fit (slope) were generated indicating where the disease in the prostate gland is hypothetically located. Quantitative data (% volume of cancer over the prostate gland) were compared to whole-mount radical prostatectomy histopathology maps to determine the sensitivity and accuracy in parametrically delineating prostate cancer. Results: Representative data indicate spectral changes were associated with the presence of co-incident disease as located on correlative histopathology whole mount sections. Of the 14 patients enrolled, 7 have been analyzed and presented here. The mean % difference between 0-MHz and MBF, with H&E, was 14% (SD 38%) and 21% (SD 24%), respectively. Gross areas of disease were readily visualized in ultrasound parametric maps and corresponded to a maximum 10dB decrease in 0-MHz or MBF. Parametric maps generated from the spectral slope offered no discrimination of disease. There were differences in scatterer size estimates and scatter concentration estimates between putative disease areas and the remaining tissue. Conclusions: Initial results suggest that there is good correlation between spectroscopic maps with disease on whole-mount specimens. This method may ultimately permit ultrasound-guided targeted biopsies to improve detection rates and non-invasive assessment of disease for radiotherapy planning.

Prospective phase I/II trial of dose-painting prostate brachytherapy guided by cancer-specific ultrasound-based tissue-type imaging (TTI).

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 246-246
Author(s):  
Ronald D. Ennis ◽  
Frieda Trichter ◽  
Kunal Saigal ◽  
Stuart A. Quinn ◽  
Ernest J. Feleppa
Keyword(s):  
Prostate Gland ◽  
Cancer Control ◽  
Low Risk ◽  
Tissue Type ◽  
Prostate Brachytherapy ◽  
Ultrasound Images ◽  
Dose Painting ◽  
Technical Problems ◽  
Psa Bounce ◽  
Standard Implant

246 Background: Standard treatments treat the entire prostate gland uniformly, while focal treatments target only the dominant tumor. We propose an alternative approach wherein tumor areas are treated with an escalated dose of radiation while the remainder of the prostate with dose de-escalation. Tissue-type images (TTIs), which identify intraprostatic tumors via ultrasound spectral analysis, were used to identify tumors. Methods: 14 low risk patients were enrolled. TTIs and standard B-mode ultrasound images were generated and fused intraoperatively. Based on TTIs, plans were developed to deliver 200% prescription dose to the tumors and 100% to the prostate. Doses above 100% to non-tumor regions were minimized and standard normal tissue constraints were respected. Results: 12 patients were successfully treated. Technical problems occurred in the first patient and another received a standard implant due to discordance of TTIs with MRI and biopsy findings. One patient passed away soon after the procedure of unrelated cause. A total of 28 tumors were identified in these 12 patients (median 2 tumors/patient, range 1-4). Mean tumor volume was 0.72cc (range 0.03cc -4.07cc). Tumor dose was significantly higher in TTI-based plans, with mean tumor V200%: TTI vs. standard 97% vs. 48%, p<0.05. Modest dose reduction of the whole prostate was also achieved. Median follow-up was 25.7 months (range 21.3-48 months). A low incidence of grade 2 toxicities and no grade 3-4 toxicities were seen (Table). Two patients experienced a biochemical failure per the nadir+2 definition, both failures are attributable to PSA bounce (PSA down to 1.0 and 0.59 at 42 and 30 mos., respectively). Post-treatment biopsies have been performed on 5/11 patients (4 refused), with 2 patients with pending biopsies. 4/5 available biopsies are negative, with 1 patient having a small focus of residual cancer. Conclusions: Dose-painting prostate brachytherapy is technically feasible. This tumor-directed approach, more rational than uniform whole gland treatments, offers the promise of excellent cancer control, low toxicity and low risk of re-treatment. Clinical trial information: NCT01227642. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document